NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Danish biotech and healthcare sector delivered a return of 4.4%. Most notably, Gubra appointed a new CEO, while IO Biotech presented positive phase 3 data, and Evaxion expressed excitement about upcoming clinical data. Additionally, SynAct Pharma raised MSEK 17.7, and Zealand Pharma presented H1 2025 results with revenues at DKK 9.1 billion following a large upfront payment by Roche. As always, new price targets were given as well.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
No news in the past week
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
No news in the past week
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization of this product.
No news in the past week
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
No news in the past week
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news in the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in its cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
Evaxion Biotech presented a business and financial quarter expressing excitement of the upcoming results of the full two-year clinical efficacy data of EVX-01 being presented in October 2025 and results of a one-year extension of the same study, allowing the company to present three-year data of EVX-01 in 2026.
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
No news in the past week
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
No news in the past week
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
No news in the past week
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline
Markus Rohrwild was appointed new CEO of Gubra in a planned succession process, and DNB Carnegie lowered their price target from DKK 750 to DKK 560.
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
No news in the past week
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
IO Biotech announced positive topline results of a pivotal phase 3 trial of Cylembio® in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for patients with advanced melanoma. Further, the company reported a financial update, seeing its current cash position as sufficient to run into 2026.
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
No news in the past week
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
SynAct Pharma raised MSEK 17.7 via conversion of warrants.
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
No news in the past week
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.
Zealand Pharma announced financial results for H1 2025 with revenues at DKK 9.1 billion following a massive upfront payment of USD 1.65 billion by its partner Roche. Additionally, DNB Carnegie lowered their price target from DKK 900 to DKK 623, SEB lowered it from DKK 780 to DKK 670, while Goldman Sachs increased its from DKK 820 to DKK 866.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news in the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks delivered a return of 4.4%. Most notably, Gubra appointed Markus Rohrwild as a new CEO. SynAct Pharma raised MSEK 17.7 via conversion of warrants, Evaxion Biotech presented a business update with excitement for the upcoming results of two-year clinical efficacy data of EVX-01, and IO Biotech with positive phase 3 results. Moreover, many new price targets were given. DNB Carnegie lowered their price target of Gubra from DKK 750 to DKK 560. Zealand Pharma received three new price targets ranging from DKK 623 to DKK 866 after they presented H1 2025 results with revenues at DKK 9.1 billion following a large upfront payment by Roche.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
